Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Javier de la Rubia(Universitat de València), Jesús F. San Miguel(Clinica Universidad de Navarra), Javier Pérez‐Calvo(GEICAM – Spanish Breast Cancer Group), Raimundo García Boyero(Hospital General Universitari de Castelló), Joan Bladé(Hospital Clínic de Barcelona), Adrían Alegre(Hospital Universitario de La Princesa), Palomera Bernal L(GEICAM – Spanish Breast Cancer Group), Hernández Mt(GEICAM – Spanish Breast Cancer Group), García Siguero Pr(GEICAM – Spanish Breast Cancer Group), Rafael Martínez(Hospital Clínico San Carlos), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Joan Besalduch(Hospital Universitario Son Dureta), Josep‐María Ribera(Universitat Autònoma de Barcelona), José García‐Laraña, Casado Lf(GEICAM – Spanish Breast Cancer Group), Pascual Fernández(Hospital General Universitario de Alicante Doctor Balmis), Lahuerta Jj(GEICAM – Spanish Breast Cancer Group), de Arriba F(GEICAM – Spanish Breast Cancer Group)
PubMed
May 1, 2006
Cited by 55
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k